Letter to the Editor
Enoxaparin in unstable angina patients with renal failure

https://doi.org/10.1016/S0167-5273(01)00455-7Get rights and content

Abstract

The dosage of the subcutaneous low molecular weight heparin enoxaparin in unstable angina patients undergoing coronary angiogram and coronary angioplasty depends clearly on the renal function. It should be significantly reduced to 64% of the standard dose (1 mg/kg per 12 h) in patients with severe renal failure (creatinine clearance<30 ml/min) to provide a safe anticoagulant profile.

References (6)

  • E.M Antman et al.

    Assessment of the treatment of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-Essence meta-analysis

    Circulation

    (1999)
  • P Mismetti et al.

    Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)

    Thromb Haemost

    (1998)
  • Dose-ranging trial of enoxaparin for unstable angina patients: results of TIMI 11A

    J Am Coll Cardiol

    (1997)
There are more references available in the full text version of this article.

Cited by (92)

  • The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial

    2007, Journal of the American College of Cardiology
View all citing articles on Scopus
View full text